

Hilary (NIH/NIAID) [E] <(b) (6)>; Lerner, Andrea (NIH/NIAID) [E]
(b) (6)>; Doepel, Laurie (NIH/NIAID) [E] (b) (6)>; Gilles, Sharon
(NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)>;
Stover, Kathy (NIH/NIAID) [E] <(b) (6)>; Law, Kim (NIH/NIAID) [E] (b) (6)>;
Lee, Kun-Lin (NIH/NIAID) [E] (b) (6)>; Bushar, Nicholas (NIH/NIAID) [E]
(b) (6)>; Schneider, Johanna (NIH/NIAID) [E] (b) (6)>

Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 3/26/20

Tony,

YTD spending is \$21.6M , a weekly increase of \$4.0M for clinical trial site set-up for therapeutics, further vaccine development, small animal development, and therapeutic development (mAbs) and basic research.

Most of the \$50M-\$60M we listed last week we expect to be awarded before March 31. In many cases contractors have begun work without the award so as to not stall work.

Early next week I'll provide a summary spending plan for the additional \$706M that NIAID received in the supplemental appropriation signed by the President today.

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, March 20, 2020 4:54 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E]
(b) (6)>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J.
(NIH/NIAID) [E] (b) (6)>; Harper, Jill (NIH/NIAID) [E] (b) (6)>; Crum,
Wayne (NIH/NIAID) [E] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E]
(b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6)>
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E]
(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Marston, Hilary
(NIH/NIAID) [E] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] <(b) (6)>;
Doepel, Laurie (NIH/NIAID) [E] <(b) (6)>; Gilles, Sharon (NIH/NIAID) [E]
<(b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Stover, Kathy
(NIH/NIAID) [E] (b) (6)>; Law, Kim (NIH/NIAID) [E] (b) (6)>; Lee, Kun-Lin
(NIH/NIAID) [E] (b) (6)>; Bushar, Nicholas (NIH/NIAID) [E] (b) (6)
Schneider, Johanna (NIH/NIAID) [E] (b) (6)>
Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 3/19/20

Tony,

YTD spending is \$17.6M , a weekly increase of \$3.5M for clinical trial site set-up, therapeutic development (mAbs) and basic research.